Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01867203
Other study ID # CYPstatin001
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date August 1, 2017
Est. completion date September 1, 2019

Study information

Verified date March 2021
Source Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Patients needing lipid lowering therapy will be recruited before initiation of the treatment. For each patient, total and LDL cholesterol levels before start of therapy will be measured. One, three and six months after his/her first visit, when steady-state will be reached, for each included patient, the cholesterol levels will be re-assessed in order to evaluate the response to statin therapy calculated as the amplitude of cholesterol reduction. The aim is to assess the association between patient's genotype and the response to statin therapy.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date September 1, 2019
Est. primary completion date August 1, 2019
Accepts healthy volunteers No
Gender All
Age group 25 Years to 80 Years
Eligibility Inclusion Criteria: - Patient known to be compliant - Age [25-80] - treated with Atorvastatin, simvastatin, fluvastatin. Exclusion Criteria: - Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Genotyping
DNA extraction from blood

Locations

Country Name City State
Belgium Saint-Luc Hospital Brussels

Sponsors (1)

Lead Sponsor Collaborator
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cholesterol levels-side effects 1 to 6 months